Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2010

Open Access 01-12-2010 | Research

Simvastatin protects bladder and renal functions following spinal cord injury in rats

Authors: Anandakumar Shunmugavel, Mushfiquddin Khan, Peter C te Chou, Ramanpreet K Dhindsa, Marcus M Martin, Anne G Copay, Brian R Subach, Thomas C Schuler, Mehmet Bilgen, John K Orak, Inderjit Singh

Published in: Journal of Inflammation | Issue 1/2010

Login to get access

Abstract

Background

Urinary bladder and renal dysfunction are secondary events associated with spinal cord injury (SCI) in humans. These secondary events not only compromise quality of life but also delay overall recovery from SCI pathophysiology. Furthermore, in experimental models the effects of SCI therapy on bladder and renal functions are generally not evaluated. In this study, we tested whether simvastatin improves bladder and renal functions in a rat model of experimental SCI.

Methods

SCI was induced by controlled contusion of T9-T10 in adult female rats. Simvastatin (5 mg/Kg body weight) was administered at two hours after SCI and repeated every 24 hours until the end point. Simvastatin-treated SCI animals (simvastatin group) were compared with vehicle-treated SCI animals (vehicle group) in terms of the Basso Beattie Bresnahan score, tissue morphology, cell death, and bladder/renal functions.

Results

The urinary bladder of vehicle animals showed a 4.3-fold increase in size and a 9-fold increase in wet weight compared to sham animals. Following SCI, the urine to plasma osmolality ratio increased initially but decreased 1 week after SCI. Hematoxylin and eosin staining of bladder tissue showed transitional epithelial hyperplasia, degeneration of lamina propria, and enlargement of tunica adventia in addition to detrusor muscle hypertrophy. Rats treated with simvastatin for 14 days displayed remarkable recovery by showing decreased bladder size and maintenance of a normal urine/plasma osmolality ratio, in addition to improved locomotion. The muscularis layer of the bladder also regained its compact nature in simvastatin animals. Moreover, SCI-induced renal caspase-3 activity was significantly decreased in the simvastatin group indicating the ability of simvastatin to reduce the renal tubular apoptosis.

Conclusion

Post-injury administration of simvastatin ameliorates bladder and renal dysfunction associated with SCI in rats.
Appendix
Available only for authorised users
Literature
1.
de Groat WC: Central neural control of the lower urinary tract. Ciba Found Symp. 1990, 151: 27-44.PubMed
2.
Vignes JR, Deloire M, Petry K: Animal models of sacral neuromodulation for detrusor overactivity. Neurourol Urodyn. 2009, 28: 8-12. 10.1002/nau.20612.PubMedCrossRef
3.
Vizzard MA, Erickson VL, Card JP, Roppolo JR, de Groat WC: Transneuronal labeling of neurons in the adult rat brainstem and spinal cord after injection of pseudorabies virus into the urethra. J Comp Neurol. 1995, 355: 629-640. 10.1002/cne.903550411.PubMedCrossRef
4.
Pikov V, Wrathall JR: Coordination of the bladder detrusor and the external urethral sphincter in a rat model of spinal cord injury: effect of injury severity. J Neurosci. 2001, 21: 559-569.PubMed
5.
Chang S, Mao ST, Hu SJ, Lin WC, Cheng CL: Studies of detrusor-sphincter synergia and dyssynergia during micturition in rats via fractional Brownian motion. IEEE Trans Biomed Eng. 2000, 47: 1066-1073. 10.1109/10.855934.PubMedCrossRef
6.
Fujita O, Asanuma M, Yokoyama T, Miyazaki I, Ogawa N, Kumon H: Involvement of STAT3 in bladder smooth muscle hypertrophy following bladder outlet obstruction. Acta Med Okayama. 2006, 60: 299-309.PubMed
7.
Imamura M, Kanematsu A, Yamamoto S, Kimura Y, Kanatani I, Ito N, Tabata Y, Ogawa O: Basic fibroblast growth factor modulates proliferation and collagen expression in urinary bladder smooth muscle cells. Am J Physiol Renal Physiol. 2007, 293: F1007-1017. 10.1152/ajprenal.00107.2007.PubMedCrossRef
8.
Lassmann J, Sliwoski J, Chang A, Canning DA, Zderic SA: Deletion of one SERCA2 allele confers protection against bladder wall hypertrophy in a murine model of partial bladder outlet obstruction. Am J Physiol Regul Integr Comp Physiol. 2008, 294: R58-65.PubMedCrossRef
9.
Mimata H, Satoh F, Tanigawa T, Nomura Y, Ogata J: Changes of rat urinary bladder during acute phase of spinal cord injury. Urol Int. 1993, 51: 89-93. 10.1159/000282520.PubMedCrossRef
10.
Schwartz K, Boheler KR, de la Bastie D, Lompre AM, Mercadier JJ: Switches in cardiac muscle gene expression as a result of pressure and volume overload. Am J Physiol. 1992, 262: R364-369.PubMed
11.
Metz GA, Curt A, Meent van de H, Klusman I, Schwab ME, Dietz V: Validation of the weight-drop contusion model in rats: a comparative study of human spinal cord injury. J Neurotrauma. 2000, 17: 1-17. 10.1089/neu.2000.17.1.PubMedCrossRef
12.
Radziszewski K, Zielinski H, Radziszewski P, Swiecicki R: Transcutaneous electrical stimulation of urinary bladder in patients with spinal cord injuries. int urol Nephrol. 2009, 41: 497-503. 10.1007/s11255-008-9488-7.PubMedCrossRef
13.
Grau JW, Washburn SN, Hook MA, Ferguson AR, Crown ED, Garcia G, Bolding KA, Miranda RC: Uncontrollable stimulation undermines recovery after spinal cord injury. J Neurotrauma. 2004, 21: 1795-1817. 10.1089/neu.2004.21.1795.PubMedCrossRef
14.
Kalsi V, Fowler CJ: Therapy Insight: bladder dysfunction associated with multiple sclerosis. Nat Clin Pract Urol. 2005, 2: 492-501. 10.1038/ncpuro0323.PubMedCrossRef
15.
Urakami S, Shiina H, Enokida H, Kawamoto K, Kikuno N, Fandel T, Vejdani K, Nunes L, Igawa M, Tanagho EA, Dahiya R: Functional improvement in spinal cord injury-induced neurogenic bladder by bladder augmentation using bladder acellular matrix graft in the rat. World J Urol. 2007, 25: 207-213. 10.1007/s00345-006-0142-7.PubMedCrossRef
16.
Nagashima M, Taziri T, Tanaka K: [A clinical study of bladder stone with spinal cord injury in subacute stage]. Hinyokika Kiyo. 2008, 54: 647-650.PubMed
17.
Jamil F: Towards a catheter free status in neurogenic bladder dysfunction: a review of bladder management options in spinal cord injury (SCI). Spinal Cord. 2001, 39: 355-361. 10.1038/sj.sc.3101132.PubMedCrossRef
18.
Pahan K, Sheikh FG, Namboodiri AM, Singh I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J clin invest. 1997, 100: 2671-2679. 10.1172/JCI119812.PubMedPubMedCentralCrossRef
19.
Weber M, Zamvil SS: Statins and demyelination. Curr Opin Neurol. 2008, 318: 313-324.
20.
Nath N, Giri S, Prasad R, Singh A, Singh I: Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. j immunol. 2004, 172: 1273-1286.PubMedCrossRef
21.
Stanislaus R, K P, Singh AK, Singh I: Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. neurosci Lett. 1999, 269: 71-74. 10.1016/S0304-3940(99)00414-0.PubMedCrossRef
22.
Paintlia A, Mk P, Singh I, Singh AK: Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol. 2008, 214: 168-180. 10.1016/j.expneurol.2008.07.024.PubMedPubMedCentralCrossRef
23.
Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M: Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007, 22: 118-127. 10.1093/ndt/gfl538.PubMedCrossRef
24.
Tsujihata M, Momohara C, Yoshioka I, Tsujimura A, Nonomura N, Okuyama A: Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol. 2008, 180: 2212-2217. 10.1016/j.juro.2008.07.024.PubMedCrossRef
25.
Zhou MS, Schuman IH, Jaimes EA, Raij L: Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008, 295: F53-59. 10.1152/ajprenal.00041.2008.PubMedPubMedCentralCrossRef
26.
Lin CL, Cheng H, Tung CW, Huang WJ, Chang PJ, Yang JT, Wang JY: Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt signaling pathway. Am J Nephrol. 2008, 28: 290-297. 10.1159/000111142.PubMedCrossRef
27.
Carrero J, Mi Y, B L, Stenvinkel P: Cytokine dysregulation in chronic kidney disease: how can we treat it?. blood purif. 2008, 26: 291-299. 10.1159/000126926.PubMedCrossRef
28.
Pannu R, Christie DK, Barbosa E, Singh I, Singh AK: Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem. 2007, 101: 182-200. 10.1111/j.1471-4159.2006.04354.x.PubMedCrossRef
29.
Pannu R, Barbosa E, Singh AK, Singh I: Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J Neurosci Res. 2005, 79: 340-350. 10.1002/jnr.20345.PubMedCrossRef
30.
Bilgen M: A new device for experimental modeling of central nervous system injuries. Neurorehabil Neural Repair. 2005, 19: 219-226. 10.1177/1545968305278635.PubMedCrossRef
31.
Basso MS, Beattie M, Bresnahan JC: A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995, 12: 1-27. 10.1089/neu.1995.12.1.PubMedCrossRef
32.
Kiernan J: Interactions between mast cells and nerves. Neurogenic inflammation. Trends Pharmacol Sci. 1990, 11: 316-10.1016/0165-6147(90)90233-X.PubMedCrossRef
33.
Rodrigues A, Suaid H, Tucci S, Fazan V, Foss M, Cologna A, Martins AC: Long term evaluation of functional and morphological bladder alterations on alloxan-induced diabetes and aging: experimental study in rats. acta cir bras. 2008, 23: 53-58.PubMedCrossRef
34.
Arner A, Sjuve Scott R, Haase H, Morano I, Uvelius B: Intracellular calcium in hypertrophic smooth muscle from rat urinary bladder. Scand J Urol Nephrol. 2007, 41: 270-277. 10.1080/00365590701225970.PubMedCrossRef
35.
Fowler CJ: Urinary retention in women. BJU Int. 2003, 91: 463-464. 10.1046/j.1464-410X.2003.04141.x.PubMedCrossRef
36.
Planas M, Wachtel T, Frank H, Henderson LW: Characterization of acute renal failure in the burned patient. Arch Intern Med. 1982, 142: 2087-2091. 10.1001/archinte.142.12.2087.PubMedCrossRef
37.
Leech S, Penney MD: Correlation of specific gravity and osmolality of urine in neonates and adults. Arch Dis Child. 1987, 62: 671-673. 10.1136/adc.62.7.671.PubMedPubMedCentralCrossRef
38.
Wilson DR, Honrath U: Inner medullary collecting duct function in ischemic acute renal failure. Clin Invest Med. 1988, 11: 157-166.PubMed
39.
Polycarpe E, Arnould L, Schmitt E, Duvillard L, Ferrant E, Isambert N, Duvillard C, Beltramo JL, Chevet D, Chauffert B: Low urine osmolarity as a determinant of cisplatin-induced nephrotoxicity. Int J Cancer. 2004, 111: 131-137. 10.1002/ijc.20202.PubMedCrossRef
40.
Guy M, Newall R, J B, Pa K, Price C: Use of a first-line urine protein-to-creatinine ratio strip test on random urines to rule out proteinuria in patients with chronic kidney disease. nephrol dial transplant. 2009, 24: 1189-1193. 10.1093/ndt/gfn612.PubMedCrossRef
41.
Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H: Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. nephrol dial transplant. 2002, 17: 798-802. 10.1093/ndt/17.5.798.PubMedCrossRef
42.
Agarwal R: Effects of statins on renal function. Am j cardiol. 2006, 97: 748-755. 10.1016/j.amjcard.2005.09.110.PubMedCrossRef
43.
Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, Corsonello A, Senatore M, Frisina N: Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. clin parmacol ther. 2000, 67: 427-431. 10.1067/mcp.2000.105330.CrossRef
44.
Choi K, Kang SW, Lee SW, Lee HY, Han DS, Kang BS: The effect of lovastatin on proliferation of cultured rat mesangial and aortic smooth muscle cells. Yonsei Med J. 1995, 36: 251-261.PubMedCrossRef
45.
Sasatomi K, Hiragata S, Miyazato M, Chancellor MB, Morris SM, Yoshimura N: Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury. Urology. 2008, 72: 696-700. 10.1016/j.urology.2007.12.002.PubMedPubMedCentralCrossRef
46.
Kim D, Sands JM, Klein JD: Changes in renal medullary transport proteins during uncontrolled diabetes mellitus in rats. Am J Physiol Renal Physiol. 2003, 285: F303-309.PubMedCrossRef
47.
Zalyapin E, Bouley R, Hasler U, Vilardaga J, Lin H, Brown DR, Ausiello DA: Effects of the renal medullary pH and ionic environment on vasopressin binding and signaling. kidney int. 2008, 74: 1557-1567. 10.1038/ki.2008.412.PubMedPubMedCentralCrossRef
48.
Moore CK, Goldman HB: The bladder epithelium and overactive bladder: what we know. Curr Urol Rep. 2006, 7: 447-449. 10.1007/s11934-006-0052-7.PubMedCrossRef
49.
Vervaet B, Verhuls t, Dauwe S, De Broe M, D'Haese PC: An active renal crystal clearance mechanism in rat and man. kidney int. 2009, 75: 41-51. 10.1038/ki.2008.450.PubMedCrossRef
50.
Khan SR: Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res. 2005, 33: 349-357. 10.1007/s00240-005-0492-4.PubMedCrossRef
51.
Singh I, As P, M K, Stanislaus , Paintlia MK, Haq E, Singh AK, Contreras MA: Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res. 2004, 1022: 1-11. 10.1016/j.brainres.2004.06.059.PubMedCrossRef
52.
Cormack A, Brinkkoetter PT, Pippin JW, Shankland SJ, Durvasula RV: Rosuvastatin protects against podocyte apoptosis in vitro. nephrol dial transplant. 2009, 24: 404-412. 10.1093/ndt/gfn528.CrossRef
53.
Lennernas H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003, 42: 1141-1160. 10.2165/00003088-200342130-00005.PubMedCrossRef
54.
Cermak R, Wein S, Wolffram S, Langguth P: Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. Eur J Pharm Sci. 2009, 38: 519-524. 10.1016/j.ejps.2009.09.018.PubMedCrossRef
55.
Dery MA, Rousseau G, Benderdour M, Beaumont E: Atorvastatin prevents early apoptosis after thoracic spinal cord contusion injury and promotes locomotion recovery. Neurosci Lett. 2009, 453: 73-76. 10.1016/j.neulet.2009.01.062.PubMedCrossRef
56.
Mahmood A, Goussev A, Kazmi H, Qu C, Lu D, Chopp M: Long-term benefits after treatment of traumatic brain injury with simvastatin in rats. Neurosurgery. 2009, 65: 187-191. 10.1227/01.NEU.0000343540.24780.D6. discussion 191-182PubMedPubMedCentralCrossRef
57.
Mann CM, Lee JH, Hillyer J, Stammers AM, Tetzlaff W, Kwon BK: Lack of robust neurologic benefits with simvastatin or atorvastatin treatment after acute thoracic spinal cord contusion injury. Exp Neurol. 2010, 221: 285-295. 10.1016/j.expneurol.2009.11.006.PubMedCrossRef
58.
Mimata H, Nomura Y, Emoto A, Latifpour J, Wheeler M, Weiss RM: Muscarinic receptor subtypes and receptor-coupled phosphatidylinositol hydrolysis in rat bladder smooth muscle. Int J Urol. 1997, 4: 591-596. 10.1111/j.1442-2042.1997.tb00315.x.PubMedCrossRef
59.
Mutoh T, Kumano T, Nakagawa H, Kuriyama M: Role of tyrosine phosphorylation of phospholipase C gamma1 in the signaling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblasts. FEBS Lett. 1999, 446: 91-94. 10.1016/S0014-5793(99)00188-X.PubMedCrossRef
60.
Braverman A, Legos J, Young W, Luthin G, Ruggieri M: M2 receptors in genito-urinary smooth muscle pathology. Life Sci. 1999, 64: 429-436. 10.1016/S0024-3205(98)00582-7.PubMedPubMedCentralCrossRef
61.
Yoshiyama M, Nezu FM, Yokoyama O, Chancellor MB, de Groat WC: Influence of glutamate receptor antagonists on micturition in rats with spinal cord injury. Exp Neurol. 1999, 159: 250-257. 10.1006/exnr.1999.7124.PubMedCrossRef
62.
Yoshimura N, Bennett NE, Hayashi Y, Ogawa T, Nishizawa O, Chancellor MB, de Groat WC, Seki S: Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci. 2006, 26: 10847-10855. 10.1523/JNEUROSCI.3023-06.2006.PubMedCrossRef
63.
Barendrecht MM, Mulders AC, Poel van der H, Hoff van den MJ, Schmidt M, Michel MC: Role of transforming growth factor beta in rat bladder smooth muscle cell proliferation. J Pharmacol Exp Ther. 2007, 322: 117-122. 10.1124/jpet.106.119115.PubMedCrossRef
64.
Hypolite J, Chang S, LaBelle E, Babu G, Periasamy M, Wein A, Chacko S: Deletion of SM-B, the high ATPase isoform of myosin, upregulates the PKC-mediated signal transduction pathway in murine urinary bladder smooth muscle. am J Physiol Renal Physiol. 2009, 296: 658-665. 10.1152/ajprenal.90221.2008.CrossRef
Metadata
Title
Simvastatin protects bladder and renal functions following spinal cord injury in rats
Authors
Anandakumar Shunmugavel
Mushfiquddin Khan
Peter C te Chou
Ramanpreet K Dhindsa
Marcus M Martin
Anne G Copay
Brian R Subach
Thomas C Schuler
Mehmet Bilgen
John K Orak
Inderjit Singh
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2010
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-7-17

Other articles of this Issue 1/2010

Journal of Inflammation 1/2010 Go to the issue

Research

Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study

Research

Regulation of apoptosis and priming of neutrophil oxidative burst by diisopropyl fluorophosphate

Research

Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: a cross sectional study

Review

Molecular imaging of transcriptional regulation during inflammation

Research

Suppression of LPS-induced matrix-metalloproteinase responses in macrophages exposed to phenytoin and its metabolite,5-(p-hydroxyphenyl-), 5-phenylhydantoin

Research

Total hip and knee replacement surgery results in changes in leukocyte and endothelial markers
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits